Targeted genome editing in acute lymphoblastic leukemia: a review
Abstract Background Genome editing technologies offers new opportunities for tackling diseases such as acute lymphoblastic leukemia (ALL) that have been beyond the reach of previous therapies. Results We show how the recent availability of genome-editing tools such as CRISPR-Cas9 are an important me...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-07-01
|
| Series: | BMC Biotechnology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12896-018-0455-9 |
| _version_ | 1819198831487614976 |
|---|---|
| author | Adrián Montaño Maribel Forero-Castro Jesús-María Hernández-Rivas Ignacio García-Tuñón Rocío Benito |
| author_facet | Adrián Montaño Maribel Forero-Castro Jesús-María Hernández-Rivas Ignacio García-Tuñón Rocío Benito |
| author_sort | Adrián Montaño |
| collection | DOAJ |
| description | Abstract Background Genome editing technologies offers new opportunities for tackling diseases such as acute lymphoblastic leukemia (ALL) that have been beyond the reach of previous therapies. Results We show how the recent availability of genome-editing tools such as CRISPR-Cas9 are an important means of advancing functional studies of ALL through the incorporation, elimination and modification of somatic mutations and fusion genes in cell lines and mouse models. These tools not only broaden the understanding of the involvement of various genetic alterations in the pathogenesis of the disease but also identify new therapeutic targets for future clinical trials. Conclusions New approaches including CRISPR-Cas9 are crucial for functional studies of genetic aberrations driving cancer progression, and that may be responsible for treatment resistance and relapses. By using this approach, diseases can be more faithfully reproduced and new therapeutic targets and approaches found. |
| first_indexed | 2024-12-23T03:06:42Z |
| format | Article |
| id | doaj.art-e029ffe9b6844b939bf1ce04375e5895 |
| institution | Directory Open Access Journal |
| issn | 1472-6750 |
| language | English |
| last_indexed | 2024-12-23T03:06:42Z |
| publishDate | 2018-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Biotechnology |
| spelling | doaj.art-e029ffe9b6844b939bf1ce04375e58952022-12-21T18:02:18ZengBMCBMC Biotechnology1472-67502018-07-0118111010.1186/s12896-018-0455-9Targeted genome editing in acute lymphoblastic leukemia: a reviewAdrián Montaño0Maribel Forero-Castro1Jesús-María Hernández-Rivas2Ignacio García-Tuñón3Rocío Benito4IBSAL, IBMCC, University of Salamanca-CSIC, Cancer Research CenterSchool of Biological Sciences (GICBUPTC Research group), Universidad Pedagógica y Tecnológica de ColombiaIBSAL, IBMCC, University of Salamanca-CSIC, Cancer Research CenterIBSAL, IBMCC, University of Salamanca-CSIC, Cancer Research CenterIBSAL, IBMCC, University of Salamanca-CSIC, Cancer Research CenterAbstract Background Genome editing technologies offers new opportunities for tackling diseases such as acute lymphoblastic leukemia (ALL) that have been beyond the reach of previous therapies. Results We show how the recent availability of genome-editing tools such as CRISPR-Cas9 are an important means of advancing functional studies of ALL through the incorporation, elimination and modification of somatic mutations and fusion genes in cell lines and mouse models. These tools not only broaden the understanding of the involvement of various genetic alterations in the pathogenesis of the disease but also identify new therapeutic targets for future clinical trials. Conclusions New approaches including CRISPR-Cas9 are crucial for functional studies of genetic aberrations driving cancer progression, and that may be responsible for treatment resistance and relapses. By using this approach, diseases can be more faithfully reproduced and new therapeutic targets and approaches found.http://link.springer.com/article/10.1186/s12896-018-0455-9Acute lymphoblastic leukemiaCRISPR-Cas9Genome editing |
| spellingShingle | Adrián Montaño Maribel Forero-Castro Jesús-María Hernández-Rivas Ignacio García-Tuñón Rocío Benito Targeted genome editing in acute lymphoblastic leukemia: a review BMC Biotechnology Acute lymphoblastic leukemia CRISPR-Cas9 Genome editing |
| title | Targeted genome editing in acute lymphoblastic leukemia: a review |
| title_full | Targeted genome editing in acute lymphoblastic leukemia: a review |
| title_fullStr | Targeted genome editing in acute lymphoblastic leukemia: a review |
| title_full_unstemmed | Targeted genome editing in acute lymphoblastic leukemia: a review |
| title_short | Targeted genome editing in acute lymphoblastic leukemia: a review |
| title_sort | targeted genome editing in acute lymphoblastic leukemia a review |
| topic | Acute lymphoblastic leukemia CRISPR-Cas9 Genome editing |
| url | http://link.springer.com/article/10.1186/s12896-018-0455-9 |
| work_keys_str_mv | AT adrianmontano targetedgenomeeditinginacutelymphoblasticleukemiaareview AT maribelforerocastro targetedgenomeeditinginacutelymphoblasticleukemiaareview AT jesusmariahernandezrivas targetedgenomeeditinginacutelymphoblasticleukemiaareview AT ignaciogarciatunon targetedgenomeeditinginacutelymphoblasticleukemiaareview AT rociobenito targetedgenomeeditinginacutelymphoblasticleukemiaareview |